Medivation, Inc.

351 articles with Medivation, Inc.

• 

  Acrivon Nets $100 Million and Licenses Cast-Off Lilly Oncology Drug

  11/11/2021

  Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.
• 

  Former Medivation Exec Charged with Insider Trading Ahead of 2016 Pfizer Acquisition

  8/17/2021

  The latest biopharma insider trading scandal stems from Pfizer’s acquisition of Medivation in 2016.
• 

  Astellas Pushes Outside of Oncology, Releases Positive Results in Anemia Trials

  9/21/2018

  Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
• 

  Axovant Licenses Gene Therapy for Parkinson’s Disease from Oxford BioMedica

  6/6/2018

  Axovant Sciences, one of Vivek Ramaswamy’s biotech startups, is taking another shot, this time at Parkinson’s disease.

• Medivation Founder Explains Why He Wants To Do Things Differently This Time

  9/11/2017

• After a Billion+ Loss to Alzheimer's at Medivation, Hung Takes Another Shot at Ramaswamy's Axovant

  9/8/2017

• Pfizer Sheds More After Unloading Medivation's Mission Bay Space

  5/10/2017

• Why Former Medivation CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant

  4/20/2017

• And He's Back! Medivation's David Hung to Helm Vivek Ramaswamy's Axovant

  4/11/2017

• JPM17: Surprise! Pfizer is Still Deal Hungry for M&As After Medivation

  1/16/2017

• Pfizer Completes Acquisition Of Medivation

  9/28/2016

• Pfizer Announces Expiration Of HSR Waiting Period For Proposed Acquisition of Medivation

  9/23/2016

• 4 Biotechs Gilead Could Be Targeting After Losing Medivation

  9/22/2016

• Pfizer May No Longer Need to Split Post-Medivation

  9/19/2016

• The 3 Most-Coveted Cancer Acquisition Targets Post-Medivation

  9/14/2016

• How Medivation and This Little Biotech Turned $8,000 Into $250,000+ for Investors

  9/13/2016

• SEC Filings Show How Medivation’s CEO and Board Backroom Dealings Drove Up Acquisition Price

  9/7/2016

• SEC Docs Say Pfizer Beat Out 4 Companies to Buy Medivation

  9/1/2016

• Medivation Exec Jumps Ship to Become CMO at BeiGene

  8/26/2016

• Just Days after a $14 Billion Medivation Buy, Pfizer Buys AstraZeneca PLC's Antibiotics Business for $1.5 Billion-Plus

  8/26/2016